期刊文献+

反相高效液相色谱法测定磷酸西他列汀的含量 被引量:4

RP-HPLC determination of sitagliptin phosphate
原文传递
导出
摘要 目的:建立测定磷酸西他列汀含量的高效液相色谱法。方法:采用SymmetryC18柱(150mm×4.6mm,5μm);流动相为甲醇-0.1%高氯酸水溶液(32∶68),流速:1.0mL·min-1,检测波长:268nm,柱温:30℃。结果:磷酸西他列汀的浓度在0.5~500μg·mL-1范围内线性良好(r=0.9996);方法的最低检测限为1ng(S/N=3);高、中、低3个浓度的平均回收率(n=5)分别为99.4%(RSD=0.22%),98.9%(RSD=0.34%),99.3%(RSD=0.10%);各杂质峰与主峰达到基线分离。结论:此方法操作简便、灵敏、准确,重复性好,适用于磷酸西他列汀的含量测定,可作为该药质量控制的检测方法。 Objective: To establish an RP-HPLC method for determination of the content of sitagliptin phosphate. Methods: The column was Symmetry C18 (150mm×4.6mm, 5μm), the mobile phase consisted of methanol - 0.1% perchloric acid solution (32:68) with a flow rate of 1.0mL·min-1, the UV detection wavelength was set at 268nm. Results: The calibration curve was linear within the range of 0.5 to 500 μg/mL (r= 0.9996); the lowest limit determination was 1ng (S/N=3). The mean recoveries (n=3) of high, middle and low concentration were 99.4% (RSD=0.22%), 98.9% (RSD=0.34%), 99.3% (RSD=0.10%); the chromatographic peaks of sitagliptin phosphate and its related substances were well isolated. Conclusion: The method is simple, selective, accurate, reproducible. It is suitable for determination of the content of sitagliptin phosphate.
出处 《药物分析杂志》 CAS CSCD 北大核心 2009年第8期1370-1372,共3页 Chinese Journal of Pharmaceutical Analysis
关键词 反相高效液相色谱法 磷酸西他列汀 含量测定 RP - HPLC sitagliptin phosphate content determination
  • 相关文献

参考文献10

  • 1夏玲红.治疗糖尿病的新药西他列汀[J].中国新药杂志,2007,16(12):979-981. 被引量:26
  • 2Green BD, Flan PR, Bailey Cj. Dipeptidyl peptidase Ⅳ ( DPP Ⅳ) inhibitors:A newly emerging drug class for the treatment of type 2 diabetes. Diab Vasc Dis Res. 2006,3 ( 3 ) : 159. 被引量:1
  • 3Rosenstock J, Brazg R, Andryuk PJ. Efficacy and safety of the dipeptidyl peptidase -4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes : a 24 - week, multicenter, randomized, double - blind, placebo - controlled, parallel - group study. Clin Ther. 2006,28 (10) : 1556. 被引量:1
  • 4Sitagliptin with metformin : profile of a combination for the treatment of type 2 diabetes. Drugs Today(Barc). 2007,43 (10) :681. 被引量:1
  • 5Raz I, Chen Y, Wu M, et al. Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes. Curr Med Res Opin. 2008,24(2) :537. 被引量:1
  • 6Mistry GC, Bergman A J, Luo WL, et al. Multiple -dose administration of sitagliptin, a dipeptidyl peptidase - 4 inhibitor, does not alter the single - dose pharmacokinetics of rosiglitazone in healthy subjects. Diabetes Obes Metab. 2007,47 ( 2 ) : 159. 被引量:1
  • 7Brazg R, Xu L, Dalla man C, et al. Effect of adding sitagliptin, a dipeptidyl peptidase- 4 inhibitor, to metformin on 24 -h glycemic control and beta - cell function in patients with type 2 diabetes. Rapid Commun Mass Spectrom. 2007,9 (2) :186. 被引量:1
  • 8Wei Zeng, Donald G Musson, Alison L Fisher, et al. Determination of MK -0431 in human plasma using high turbulence liquid chromatography online extraction and tandem mass spectrometry. Rapid Commun Mass Spectrom. 2006,20 ( 8 ) : 1169. 被引量:1
  • 9Ramakrisboa Nirogi, Vishwottam Kandikere, Koteshwara Mudigonda,et al. Sensitive liquid chromatography tandem mass spectrometry method for the quantification of sitagliptin, a DPP - 4 inhibitor, in human plasma using liquid - liquid extraction. Biomed Chromatogr. 2007,22(2) :214. 被引量:1
  • 10Herman GA, Stevens C, Van Dyck K, et al. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase Ⅳ, in healthy subjects : results from two randomized, double - blind, placebo- controlled studies with single oral doses. Clin Pharmacol Ther. 2005,78 (6) :675. 被引量:1

二级参考文献10

  • 1HERMAN GA,BERGMAN A,STEVENS C,et al.Effect of single oral doses of sitagliptin,a dipeptidyl peptidase-4 inhibitor,on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes[J].J Clin Endocrinol Metab,2006,91 (11):4612-4619. 被引量:1
  • 2BERGMAN AJ,STEVENS C,ZHOU Y,et al.Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin,a dipeptidyl peptidase-Ⅳ inhibitor:a double-blind,randomized,placebo-controlled study in healthy male volunteers[J].Clin Ther,2006,28(1):55 -72. 被引量:1
  • 3HERMAN GA,BERGMAN A,LIU F,et al.Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitaglipin in middle-aged obese subjects[J].J Clin Pharmacol,2006,46(8):876 -886. 被引量:1
  • 4HERMAN GA,STEVENS C,VAN DYCK K,et al.Pharmacokinetics and pharmacodynamics of sitagliptin,an inhibitor of dipeptidyl peptidase Ⅳ,in healthy subjects:results from two randomized,double-blind,placebo-controlled studies with single oral doses[J].Clin Pharmacol Ther,2005,78(6):675 -688. 被引量:1
  • 5VINCENT SH,REED JR,BERGMAN AJ,et al.Metabolism and excretion of the DPP-4 inhibitor[14C] sitagliptin in humans[J].Drug Metab Dispos,2007,35(4):533 -538. 被引量:1
  • 6RAZ I,HANEFELD M,XU L,et al.Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitsgliptin as monotherapy in patients with type 2 diabetes mellitus[J].Diabetologia,2006,49(11):2564 -2571. 被引量:1
  • 7ASCHNER P,KIPNES MS,LUNCEFORD JK,et al.Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes[J].Diabetes Care,2006,29(12):2632 -2637. 被引量:1
  • 8SCOTT R,WU M,SCANCHEZ M,et al.Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes[J].Int J Clin Pract,2007,61(1):171 -180. 被引量:1
  • 9CHARBONNEL B,KARASIK A,LIU J,et al.Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone[J].Diabetes Care,2006,29(12):2638 -2643. 被引量:1
  • 10ROSENSTOCK J,BRAZG R,ANDRYUK PJ,et al.Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2diabetes:a 24-week,multicenter,randomized,doubleblind,placebo-controlled,parallel-group study[J].Clin Ther,2006,28(10):1556-1568. 被引量:1

共引文献25

同被引文献24

引证文献4

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部